每日步数:局部晚期非小细胞肺癌的新预后因素?
本研究在局部晚期非小细胞肺癌(NSCLC)接受根治性同步放化疗的患者中,用可穿戴设备采集基线步数,按健康人群百分位分为不活动、中等活动和高活动三组。50例受试者中不活动组住院率更高、放疗延误更常见,无进展生存和总生存均显著更差;体能状态不是显著预测因素。
要点
- 可穿戴设备测得的基线活动水平可能识别适合同步放化疗的NSCLC患者。
- 不活动组放疗期间住院率50%对9%,未延误超1周完成放疗67%对97%。
- 不活动组中位PFS 5.3对18.3个月,中位OS 15.0个月对未达到。
核心结论
- 基线活动水平可用可穿戴设备测量,可能有助于识别适合同步放化疗的NSCLC患者并预测临床结局。
研究设计与样本
- 研究为临床试验的一部分,局部晚期NSCLC患者在根治性同步放化疗期间佩戴商用健身追踪器。
- 基线步数均值定义为从入组至放疗第一周完成期间的平均每日总步数。
- 依据健康个体数据将受试者分为不活动(低于第25百分位)、中等活动(第25至75百分位)和高活动(高于第75百分位)。
- 共50例受试者符合纳入标准,采用Fisher精确检验、Kaplan-Meier法和Cox比例风险模型分析。
主要发现
- 9例(18%)为高活动,23例(46%)为中等活动,18例(36%)为不活动。
- 不活动者放疗期间住院率高于其他受试者(50%对9%,P = .004)。
- 不活动者未延误超过1周完成放疗的比例低于其他受试者(67%对97%,P = .006)。
- 不活动者中位PFS为5.3个月,其他受试者为18.3个月(不活动风险比=5.10,P < .001)。
- 不活动者中位OS为15.0个月,其他受试者未达到(风险比=3.91,P = .004);体能状态不是PFS或OS的显著预测因素。
关键数值与推荐
- 不活动定义为基线平均每日步数低于健康个体第25百分位。
- 中等活动定义为第25至75百分位,高活动定义为高于第75百分位。
- 住院比较:不活动组50%对9%,P = .004。
- 放疗未延误超过1周完成比较:不活动组67%对97%,P = .006。
- PFS风险比5.10(P < .001),OS风险比3.91(P = .004)。
临床怎么用
- 可考虑用商用可穿戴设备采集基线步数,辅助识别适合同步放化疗的局部晚期NSCLC患者。
- 基线不活动者放疗期间住院风险更高、放疗延误更常见,可能需要加强支持与监测。
局限性
- 研究样本量为50例,属于临床试验的一部分。
- 活动分组依据健康个体百分位,未报告其他阈值验证。
- 原文未报告检索范围等综述类信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Here we explore the prognostic value of baseline step count data captured using wearable devices for patients treated with definitive chemoradiation therapy for locally advanced non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Patients with locally advanced NSCLC wore a commercial fitness tracker during a course of definitive, concurrent chemoradiation therapy as part of a clinical trial. Baseline step count average was defined as the average daily step total from study enrollment until completion of the first week of radiation therapy. Based on data from healthy individuals, study subjects were categorized as inactive (below the 25th percentile), moderately active (25th to 75th percentile), or highly active (above the 75th percentile). Fisher's exact test was used to examine activity level as a predictor of hospitalization during radiation therapy and of completing the planned radiation therapy course without delay exceeding 1 week. Median progression-free survival (PFS) and overall survival (OS) durations were estimated using the Kaplan-Meier method. Inactivity was tested as a predictor of PFS and OS using Cox proportional hazards models. RESULTS: Fifty subjects met eligibility criteria. Nine (18%) were categorized as highly active, 23 (46%) were moderately active, and 18 (36%) were inactive. Inactive subjects were more likely to be hospitalized during the radiation therapy course than other subjects (50% vs 9%, P = .004) and less likely to complete radiation therapy without delay exceeding 1 week (67% vs 97%, P = .006). Median PFS duration was 5.3 months for inactive subjects and 18.3 months for others (hazard ratio for inactivity = 5.10, P < .001). Median OS duration was 15.0 months for inactive subjects and not reached for others (hazard ratio = 3.91, P = .004). Performance status was not a significant predictor of PFS or OS. CONCLUSIONS: Baseline activity level measured using wearable devices may help identify patients with NSCLC who are fit for concurrent chemoradiation therapy and can predict clinical outcomes in this setting.
引用
- Ohri N, Halmos B, Bodner WR, et al. Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer? Int J Radiat Oncol Biol Phys. 2019. PMID: 31398385. doi:10.1016/j.ijrobp.2019.07.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。